食管神经内分泌癌90例临床预后分析  

The Clinical Features and Prognosis of 90 Cases with Neuroendocrine Carcinoma of the Esophagus

作　　者：缪璐璐[1] 范云[1] 黄志煜[1] 杨海燕[1] 余海峰[1] 

机构地区：[1]浙江省肿瘤医院,浙江杭州310022

出　　处：《肿瘤学杂志》2011年第10期766-769,共4页Journal of Chinese Oncology

摘　　要：[目的]探讨食管神经内分泌癌的临床特点、治疗方法及预后。[方法]回顾性分析1995年1月至2011年1月间收治的90例食管神经内分泌癌的临床和随访资料。[结果]全组患者中位生存时间为10.0个月;1、3、5年生存率分别为44.6%、21.6%和14.4%。局限期患者中位生存时间为11.5个月,广泛期患者中位生存时间为6.0个月,差异有统计学意义(P<0.05)。局限期患者接受单一治疗、综合治疗的中位生存时间分别为9.8个月和16.7个月,差异有统计学意义(P<0.05)。[结论]食管神经内分泌癌恶性程度高、预后差,综合治疗较单一治疗方案可提高患者生存率。[Purpose] To investigate the clinical features,method of treatment and prognosis in patient with neuroendocrine carcinoma of the esophagus. [Methods] The clinical data of 90 cases with neuroendocrine carcinoma the esophagus from January 1995 to January 2011 were retrospectively analyzed. [Results] The 1-,3- and 5-year survival rates were 44.6%,21.6% and 14.4% respectively, with a median survival of 10.0 months. The median survival was 11.5 months in patient with locally stage and 6.0 months in patient with advanced stage, with significant difference （P〈0.05）. The median survival of locally stage patient with single treatment modality and with comprehensive treatment modality was 9.8 months and 16.7 months respectively（P〈0.05）.[Conclusion] Neuroendocrine carcinoma of the esophagus is a systemic disease with aggressive behavior and poor prognosis.Comprehensive treatment is superior to single modality treatment in survival rate.

关 键 词：神经内分泌癌 食管 治疗 预后 

分 类 号：R735.1[医药卫生—肿瘤]